报价延迟最少15分钟:2026/04/25 20:28 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.78 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.30/-2.35
|
|
企业价值
720.14M
|
| 资产负债 |
|
每股账面净值
5.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects. |
